The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).
 
Katelyn Mae Atkins
No Relationships to Disclose
 
Jun Gong
Honoraria - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants
 
Mourad Tighiouart
No Relationships to Disclose
 
Samuel J. Klempner
Stock and Other Ownership Interests - TP Therapeutics; TP Therapeutics; TP Therapeutics; TP Therapeutics
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Lilly; Lilly; Lilly; Lilly
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst)
 
Richard Tuli
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Patents, Royalties, Other Intellectual Property - patent pending: Methods of Treating Gastrointestinal Malignancies Application No.: 16/256,840 Filed: January 24, 2019 Inventor(s): Tuli, Richard (Inst); patent pending: Methods of Treating Gastrointestinal Malignancies Application No.: 16/256,840 Filed: January 24, 2019 Inventor(s): Tuli, Richard (Inst); patent pending: Methods of Treating Gastrointestinal Malignancies Application No.: 16/256,840 Filed: January 24, 2019 Inventor(s): Tuli, Richard (Inst); patent pending: Methods of Treating Gastrointestinal Malignancies Application No.: 16/256,840 Filed: January 24, 2019 Inventor(s): Tuli, Richard (Inst)
 
Veronica Placencio-Hickok
Patents, Royalties, Other Intellectual Property - Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst)
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis; Perthera; Perthera; Perthera; Perthera
Research Funding - Ipsen; Ipsen; Ipsen; Ipsen
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme